Position in FTRE
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$516,752
-$142,681 QoQ
Shares Held
54,857
+43.5% QoQ
Ownership
0.058%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026State of Wyoming holds $10,984,351 across 71 Biotechnology names. FTRE ranks #3 (4.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDXG |
Mimedx Group, Inc.
|
163,115 | $644,304 | |
| 2 | ADMA |
Adma Biologics, Inc.
|
60,978 | $549,411 | |
| 3 | FTRE |
Fortrea Holdings Inc.
This page
|
54,857 | $516,752 | |
| 4 | PBYI |
Puma Biotechnology, Inc.
|
75,808 | $484,413 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
7,258 | $469,084 | |
| 6 | ARQT |
Arcutis Biotherapeutics, Inc.
|
18,434 | $434,305 | |
| 7 | STOK |
Stoke Therapeutics, Inc.
|
13,262 | $431,810 | |
| 8 | ZYME |
Zymeworks Inc.
|
17,148 | $429,385 |
All Filings in FTRE
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $516,752 | 54,857 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $659,433 | 38,228 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $433,074 | 51,434 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $363,771 | 73,638 | Shares | Sole | 2025-08-19 | |
| 2025-03-31 | $189,127 | 25,050 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $156,137 | 8,372 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $612,060 | 30,603 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $286,031 | 12,255 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $444,149 | 11,065 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $402,117 | 11,522 | Shares | Sole | 2024-02-15 | |
| No filing history on record for this holder in this stock. | ||||||